An interventional study of Innovative periodontal monitoring (SuP innovative) in Periodontal Disease, sponsored by Hospices Civils de Lyon. Not yet recruiting at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Periodontal Diseases with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Periodontal Diseases · France.
Among the 21 studies in Periodontal Diseases with a site in France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, and was the 19th registered.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
Browse Periodontal Diseases studies →6 of the 21 studies in Periodontal Diseases with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–80 · Healthy volunteers
CHU de Reims · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 516 is above the median of 45 across 559 interventional studies indexed under Periodontal Diseases.
Median enrollment 50 across the 13 interventional studies, 106 across the 8 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 3 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Periodontal Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07602309University Hospital, Strasbourg, FranceTedlar Bag Stability of Volatile Sulfur Compounds for Remote Halitosis Diagnosis | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Periodontal Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.
Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.
Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.
Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.
The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.
Diabetes is a disease in which the majority of these patients have type 2 diabetes, linked to poor use of insulin by the body.
Periodontitis is a chronic disease characterized by an immuno-inflammatory reaction with local production of inflammatory mediators (IL6, TNF-alpha, etc.) and contributes to the increase in the systemic inflammatory load with increased levels of C-reactive protein.
Periodontitis is frequently found in diabetic patients; it is considered a complication of diabetes. Poor glycemic control in diabetes is associated with poor periodontal health, while periodontal infection is associated with dysglycemia and increased insulin resistance.
Periodontal treatment has been shown to reduce HbA1C levels and thus the risk of complications in diabetic patients.
However, periodontitis is a recurring disease; The implementation of periodontal monitoring (SuP) is essential throughout life after periodontal treatment, in order to prevent relapses. This monitoring, which must be carried out for life, includes the reassessment of periodontal criteria, professional instrumentation and oral hygiene (HBD) advice.
Visits every 3 months are generally recommended at the beginning, in order to regularly reinforce HBD advice. However, adherence to the SuP is difficult to obtain in the long term. In orthodontic patients, the use of reminder systems (SMS, emails, mobile applications, etc.) has a positive effect on HBD and periodontal criteria and would improve the rate of attendance at appointments in the medium term (3-12 months). A reminder and reinforcement system for HBD advice could therefore be integrated into the SuP in order to improve HBD and longer-term adherence in diabetic patients.
The main objective is to evaluate the impact of innovative periodontal monitoring (with reminder systems and reinforcement of advice by SMS) versus standard periodontal monitoring on the glycemic control of diabetic patients treated for periodontitis, 2 years after the start of periodontal monitoring.
This is a comparative experimental study to evaluate the effectiveness of a new monitoring strategy for type 2 diabetic patients who have been treated for periodontitis, a randomized controlled trial including an implementation study using a mixed methods approach (quantitative and qualitative).
The research will take place in 7 hospitals (Lille, Lyon, Nantes, Paris, Rennes, Strasbourg, Toulouse) and 7 privates dental centers in France.
Two types of care are proposed after periodontal treatment (all patients included will have previously benefited from standard periodontal treatment in the different centers).
The two groups compared will be:
The primary endpoint is the HbA1c level (expressed in %) at 2 years after the date of randomization. The HbA1c level at 2 years will be collected by performing a routine dosage, in the patient's usual laboratory.
The target population of the GlyCoSuP project concerns adults with type 2 diabetes who have been treated for periodontitis.
After increasing by 10% to take into account those lost to follow-up, the total number of patients to be included will be 516 (258 patients per arm).
The duration of the inclusion period will be 24 months and the participation for each subject will be 24 months. In total, the total duration of the study will be 48 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For the Experimental Group: Innovative periodontal monitoring (SuP), consisting of: * visits every 3 months during 24 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary. (common to the control group) * sending of different types of SMS: different types of SMS messages will be sent alternately. The SMS messages are intended for patients in the experimental group. The proposed approach aims to maintain contact with the patient at home and strengthen their commitment to a good oral hygiene routine over the long term. Text messages will be sent via the French CURECALL platform. The various text messages will be scheduled from the beginning of the periodontal follow-up.
Procedure: Innovative periodontal monitoring (SuP innovative)
For the Control Group: Standard periodontal follow-up (SuP), consisting of: visits every 3 months with reinforcement of HBD advice and professional instrumentation - supra- and subgingival debridement if necessary (common to the experimental group).
Different types of SMS messages will be sent alternately. * Type 1 SMS: SMS providing targeted medical information specifically for diabetic patients. * Type 2 SMS: Interactive SMS text messages written in the form of questions. * Type 3 SMS: Before each scheduled periodontal follow-up visit (every 3 months), a reminder SMS will be sent with the date, time, and location of the appointment. The SMS messages are intended for patients in the experimental group. Over these 24 months, the following are planned per patient: * 1 Type 1 SMS/week (medical advice or information); * 1 Type 2 SMS/month (interactive with suggested answers); * 1 Type 3 SMS every 3 months (appointment reminder): 1 per visit. The various text messages will be scheduled from the beginning of the periodontal follow-up.
Also known as: Innovative periodontal monitoring (SuP innovative
HbA1c level (expressed as a %)
The HbA1c level will be collected by routine testing in the patient's usual laboratory. This endpoint will be collected without knowing the patient's group. To limit missing data, a letter will be sent to the healthcare professional responsible for the patient's diabetes management (of the two groups) at the time of inclusion. If necessary, their physician may be contacted to retrieve this data, with the patient's consent. During the previous visit, the patient will be reminded to bring their test results for the next visit. This will also be noted in the appointment reminder text message.
Time frame: At 2 years after the date of randomization.
Periodontal criteria: - average probing depth (mm),
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices. Collected by the investigator at inclusion and then every 3 months up to 24 months post-randomization.
Time frame: At inclusion and then every 3 months up to 24 months post-randomization.
Periodontal criteria: - bleeding index on probing (%),
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.
Time frame: At inclusion then every 3 months until up to 24 months post-randomization.
Periodontal criteria: - average clinical attachment level (mm),
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.
Time frame: At inclusion and then every 3 months up to 24 months post-randomization.
Periodontal criteria: - number of sites with a probing depth strictly greater than or equal to 4 mm (but with bleeding on probing),
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.
Time frame: at inclusion and then every 3 months up to 24 months post-randomization.
Periodontal criteria: - number of tooth loss,
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.
Time frame: at inclusion and then every 3 months up to 24 months post-randomization.
Periodontal criteria: - number of sites re-instrumented by debridement/root planing
The periodontal probe used will be identical for all centers (purchase included in the study-funded budget): a manual periodontal probe with constant pressure, thus reinforcing standardization of practices.
Time frame: at inclusion and then every 3 months up to 24 months post-randomization.
Diabetic Pathology Criteria: - HbA1c level (%),
HbA1c level (%): data collected from routine laboratory tests performed as part of diabetes management, in accordance with the recommendations of the French National Authority for Health (HAS), As a last resort, the physician may be contacted with the patient's consent to ensure that there have been no changes to the prescription since the last visit.
Time frame: At inclusion then every 3 months until 24 months post-randomization.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2025; primary completion for Oct 2029, 48 months later.
Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 48 months is above that.
Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.